People Living With HIV


The primary purpose of this study is to compare the size of the participants’ HIV latent reservoirs before and after receiving 8 cycles of IL-2. In order to measure the size of the HIV reservoir, all participants will undergo a leukapheresis procedure prior to taking IL-2. These results will be compared with results from another leukapheresis procedure after the participant completes theIL-2 cycles.

AIDS 400: An open-label pilot study of HIV reservoir reduction ...


Latitude Study A5359: Long-acting injectable anti-HIV medicine April 30, 2019 The CWRU/UH AIDS Clinical Trials Unit announced today the opening of a new clinical trial for people living with HIV called the Latitude study. The study will be the first in northeast Ohio to use long-acting, injectable anti-HIV medicines. The […]

Latitude Study A5359: Long-acting, injectable ART



Protocol Summary: Trio (ACTG5377) is a Phase I, first-in-human, ascending-dose study of a tri-specific broadly neutralizing antibody, in participants living with HIV. This trial will look at a human-made antibody called SAR441236. Unlike the antibodies created by a person’s immune system that attach to HIV at one part, SAR441236 has […]

Trio A5377: A Phase I, first-in-human, ascending-dose study of a ...


Protocol Summary: This study will compare the use of long-acting, injectable anti-HIV medicines with anti-HIV medicines in daily pill form for people living with HIV who have not been previously adherent (keeping up) with their anti-HIV medicines in daily pill form. Purpose of This Study: Anti-HIV medicines taken as pills […]

Latitude A5359: To see if long-acting, injectable ARTs are helpful ...